Literature DB >> 3856277

Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside.

I Hellström, V Brankovan, K E Hellström.   

Abstract

Three mouse monoclonal IgG3 antibodies, 2B2, IF4, and MG-21, recognize a GD3 ganglioside antigen that is expressed at the cell surface of most human melanomas. All three antibodies mediate antibody-dependent cellular cytotoxicity (ADCC) in vitro when tested with human lymphocytes as effector cells in a 2-hr or 4-hr 51Cr-release test, and one antibody, MG-21, also gives strong complement-dependent cytotoxicity with human serum. Antibody 2B2, which gives ADCC also in the presence of mouse lymphocytes, inhibited the outgrowth of a human melanoma in nude mice, but antibody IF4, which showed no ADCC with mouse lymphocyte effectors, did not.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3856277      PMCID: PMC397290          DOI: 10.1073/pnas.82.5.1499

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  12 in total

Review 1.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

2.  Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.

Authors:  E Nudelman; S Hakomori; R Kannagi; S Levery; M Y Yeh; K E Hellström; I Hellström
Journal:  J Biol Chem       Date:  1982-11-10       Impact factor: 5.157

3.  A cell-surface antigen which is present in the ganglioside fraction and shared by human melanomas.

Authors:  M Y Yeh; I Hellström; K Abe; S Hakomori; K E Hellström
Journal:  Int J Cancer       Date:  1982-03-15       Impact factor: 7.396

4.  Studies of a high molecular weight human melanoma-associated antigen.

Authors:  I Hellström; H J Garrigues; L Cabasco; G H Mosely; J P Brown; K E Hellström
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

5.  Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies.

Authors:  J P Brown; K Nishiyama; I Hellström; K E Hellström
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

6.  Lymphocyte-dependent antibodies to antigen 3.1, a cell-surface antigen expressed by a subgroup of human melanomas.

Authors:  I Hellström; K E Hellström; M Y Yeh
Journal:  Int J Cancer       Date:  1981-03-15       Impact factor: 7.396

7.  Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas.

Authors:  H J Garrigues; W Tilgen; I Hellstróm; W Franke; K E Hellström
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

8.  Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms.

Authors:  R G Woodbury; J P Brown; M Y Yeh; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

9.  Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody.

Authors:  W G Dippold; A Knuth; K H Meyer zum Büschenfelde
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

10.  Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.

Authors:  W G Dippold; K O Lloyd; L T Li; H Ikeda; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

View more
  26 in total

1.  Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.

Authors:  C J Honsik; G Jung; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

2.  Identification of serum components that inhibit the tumoricidal activity of amphiphilic alpha helical peptides.

Authors:  K A Peck-Miller; R P Darveau; H P Fell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.

Authors:  Zhiping Zhou; Neal Luther; George M Ibrahim; Cynthia Hawkins; Rajeev Vibhakar; Michael H Handler; Mark M Souweidane
Journal:  J Neurooncol       Date:  2012-12-12       Impact factor: 4.130

4.  Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.

Authors:  C O Yun; K F Nolan; E J Beecham; R A Reisfeld; R P Junghans
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

5.  Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.

Authors:  K Kitamura; P O Livingston; S R Fortunato; E Stockert; F Helling; G Ritter; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

6.  Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker.

Authors:  Geng Zhang; Hongtao Zhang; Qiang Wang; Priti Lal; Ann M Carroll; Margarita de la Llera-Moya; Xiaowei Xu; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-18       Impact factor: 11.205

7.  A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I. Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the pancreas.

Authors:  K Bosslet; H F Kern; E J Kanzy; A Steinstraesser; A Schwarz; G Lüben; H U Schorlemmer; H H Sedlacek
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.

Authors:  S Ohta; A Honda; Y Tokutake; H Yoshida; N Hanai
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Translational regulation of human papillomavirus type 16 E7 mRNA by the peptide SEQIKA, shared by rabbit alpha(1)-globin and human cytokeratin 7.

Authors:  Darja Kanduc
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 10.  Fc gamma receptors in cancer and infectious disease.

Authors:  M W Fanger; D V Erbe
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.